Siegfried Holding AG Stock price

Equities

SFZN

CH0014284498

Pharmaceuticals

Delayed Swiss Exchange 12:30:28 2024-03-28 pm EDT 5-day change 1st Jan Change
921 CHF +1.49% Intraday chart for Siegfried Holding AG +1.60% +7.16%
Sales 2024 * 1.3B 1.44B Sales 2025 * 1.42B 1.58B Capitalization 3.95B 4.38B
Net income 2024 * 148M 164M Net income 2025 * 172M 191M EV / Sales 2024 * 3.3 x
Net Debt 2024 * 351M 389M Net Debt 2025 * 313M 348M EV / Sales 2025 * 3 x
P/E ratio 2024 *
26.6 x
P/E ratio 2025 *
22.9 x
Employees 3,945
Yield 2024 *
0.41%
Yield 2025 *
0.44%
Free-Float 87.75%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.49%
1 week+1.60%
Current month+3.95%
1 month+3.43%
3 months+8.35%
6 months+18.92%
Current year+7.16%
More quotes
1 week
889.50
Extreme 889.5
921.50
1 month
880.00
Extreme 880
950.00
Current year
827.00
Extreme 827
950.00
1 year
631.50
Extreme 631.5
950.00
3 years
566.00
Extreme 566
950.00
5 years
313.50
Extreme 313.5
950.00
10 years
136.20
Extreme 136.2
950.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 52 10-07-31
Director of Finance/CFO 53 17-04-30
Chief Tech/Sci/R&D Officer 56 19-03-31
Members of the board TitleAgeSince
Director/Board Member 55 15-12-31
Director/Board Member 63 13-12-31
Chairman 61 09-12-31
More insiders
Date Price Change Volume
24-03-28 921 +1.49% 5,063
24-03-27 907.5 -0.66% 4,236
24-03-26 913.5 +0.22% 5,001
24-03-25 911.5 +2.36% 5,836
24-03-22 890.5 -1.77% 10,821

Delayed Quote Swiss Exchange, March 28, 2024 at 12:30 pm EDT

More quotes
Siegfried Holding AG is a Switzerland-based life sciences company which is active in primary and secondary drug manufacturing. The Company produces both drug substances and drug products. The drug substance portfolio includes contract development and manufacturing of both active pharmaceutical ingredients (APIs) and intermediates. The drug products portfolio comprises licensing and contract or co-development and manufacturing of oral solids and sterile. The Company's products and substances are developed for treatment of hypertension, benign prostate hyperplasia, depression, chronic myeloid leukemia, glaucoma, asthma, schizophrenia and bipolar disorders and diabetes. The Company operates production facilities in Switzerland, Germany, France, Malta, the United States, China, and Spain.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
921 CHF
Average target price
993.4 CHF
Spread / Average Target
+7.86%
Consensus
  1. Stock
  2. Equities
  3. Stock Siegfried Holding AG - Swiss Exchange